Cytosorbents CorporationCTSONASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-27.26%
↓ 368% below average
Average (39q)
10.17%
Historical baseline
Range
High:350.04%
Low:-71.77%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -27.26% |
| Q2 2025 | -24.11% |
| Q1 2025 | 28.20% |
| Q4 2024 | -29.93% |
| Q3 2024 | 21.87% |
| Q2 2024 | -32.40% |
| Q1 2024 | -45.08% |
| Q4 2023 | 9.13% |
| Q3 2023 | 2.19% |
| Q2 2023 | -12.95% |
| Q1 2023 | 23.88% |
| Q4 2022 | 3.40% |
| Q3 2022 | -21.35% |
| Q2 2022 | -1.41% |
| Q1 2022 | -30.86% |
| Q4 2021 | 43.99% |
| Q3 2021 | 15.22% |
| Q2 2021 | 62.10% |
| Q1 2021 | -15.03% |
| Q4 2020 | 53.17% |
| Q3 2020 | -27.12% |
| Q2 2020 | 22.44% |
| Q1 2020 | -44.77% |
| Q4 2019 | 11.71% |
| Q3 2019 | 8.70% |
| Q2 2019 | 21.12% |
| Q1 2019 | -0.21% |
| Q4 2018 | 24.76% |
| Q3 2018 | 23.29% |
| Q2 2018 | -11.46% |
| Q1 2018 | -26.48% |
| Q4 2017 | 350.04% |
| Q3 2017 | 10.32% |
| Q2 2017 | 3.85% |
| Q1 2017 | -71.77% |
| Q4 2016 | 41.89% |
| Q3 2016 | 7.33% |
| Q2 2016 | 27.55% |
| Q1 2016 | -31.62% |
| Q4 2015 | 44.52% |